BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 24882718)

  • 1. Alternative approaches to prevent androgen action in prostate cancer: are we there yet?
    Elbanna M; Heemers HV
    Discov Med; 2014 May; 17(95):267-74. PubMed ID: 24882718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Androgen action in the prostate gland.
    Yadav N; Heemers HV
    Minerva Urol Nefrol; 2012 Mar; 64(1):35-49. PubMed ID: 22402316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
    Shafi AA; Yen AE; Weigel NL
    Pharmacol Ther; 2013 Dec; 140(3):223-38. PubMed ID: 23859952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails.
    Niu Y; Chang TM; Yeh S; Ma WL; Wang YZ; Chang C
    Oncogene; 2010 Jun; 29(25):3593-604. PubMed ID: 20440270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Androgen receptor as a therapeutic target.
    Gao W
    Adv Drug Deliv Rev; 2010 Oct; 62(13):1277-84. PubMed ID: 20708648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting androgen receptor action for prostate cancer treatment: does the post-receptor level provide novel opportunities?
    Heemers HV
    Int J Biol Sci; 2014; 10(6):576-87. PubMed ID: 24948870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel selective androgen receptor modulator (SARM) MK-4541 exerts anti-androgenic activity in the prostate cancer xenograft R-3327G and anabolic activity on skeletal muscle mass & function in castrated mice.
    Chisamore MJ; Gentile MA; Dillon GM; Baran M; Gambone C; Riley S; Schmidt A; Flores O; Wilkinson H; Alves SE
    J Steroid Biochem Mol Biol; 2016 Oct; 163():88-97. PubMed ID: 27106747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structures of androgen receptor bound with ligands: advancing understanding of biological functions and drug discovery.
    Sakkiah S; Ng HW; Tong W; Hong H
    Expert Opin Ther Targets; 2016 Oct; 20(10):1267-82. PubMed ID: 27195510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a RhoA- and SRF-dependent mechanism of androgen action that is associated with prostate cancer progression.
    Heemers HV
    Curr Drug Targets; 2013 Apr; 14(4):481-9. PubMed ID: 23469924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The importance of non-nuclear AR signaling in prostate cancer progression and therapeutic resistance.
    Zarif JC; Miranti CK
    Cell Signal; 2016 May; 28(5):348-356. PubMed ID: 26829214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plumbagin improves the efficacy of androgen deprivation therapy in prostate cancer: A pre-clinical study.
    Abedinpour P; Baron VT; Chrastina A; Rondeau G; Pelayo J; Welsh J; Borgström P
    Prostate; 2017 Dec; 77(16):1550-1562. PubMed ID: 28971491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Androgen deprivation therapy for advanced prostate cancer: why does it fail and can its effects be prolonged?
    Singer EA; Golijanin DJ; Messing EM
    Can J Urol; 2008 Dec; 15(6):4381-7. PubMed ID: 19046491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Manipulation of androgens and alterations in the androgen receptor axis in prostate cancer.
    Nguyen MM; Wang Z
    Minerva Urol Nefrol; 2008 Mar; 60(1):15-29. PubMed ID: 18427432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
    Vis AN; Schröder FH
    BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Androgen receptor structural and functional elements: role and regulation in prostate cancer.
    Dehm SM; Tindall DJ
    Mol Endocrinol; 2007 Dec; 21(12):2855-63. PubMed ID: 17636035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.
    Thelen P; Heinrich E; Bremmer F; Trojan L; Strauss A
    Prostate; 2013 Nov; 73(15):1699-709. PubMed ID: 23868789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen action and metabolism in prostate cancer.
    Green SM; Mostaghel EA; Nelson PS
    Mol Cell Endocrinol; 2012 Sep; 360(1-2):3-13. PubMed ID: 22453214
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-by-cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression.
    Derderian S; Benidir T; Scarlata E; Altaylouni T; Hamel L; Zouanat FZ; Brimo F; Aprikian A; Chevalier S
    J Pathol Clin Res; 2023 Jul; 9(4):285-301. PubMed ID: 37073437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analyzing the Androgen Receptor Interactome in Prostate Cancer: Implications for Therapeutic Intervention.
    Dahiya UR; Heemers HV
    Cells; 2022 Mar; 11(6):. PubMed ID: 35326387
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen receptor: role and novel therapeutic prospects in prostate cancer.
    Taplin ME
    Expert Rev Anticancer Ther; 2008 Sep; 8(9):1495-508. PubMed ID: 18759700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.